AstraZeneca
Summary
iPR Pharmaceuticals, part of AstraZeneca, became the first pharmaceutical company in Puerto Rico to receive Renewable Liquified Natural Gas (RNLG) from landfill to fuel its cogeneration plant.
“In powering our cogenerator with RLNG, we firmly continue our path to reduce our carbon footprint as part of our commitment to achieve greater sustainability. AstraZeneca is taking bold action on climate because we recognize the connection between healthy people and a healthy planet,” said Sara Miranda, President and General Manager of iPR Pharmaceuticals.
iPR secured the RNLG supply from gases generated by the natural biodegradation processes occurring in the Humacao Landfill. Production of Renewable Liquified Natural Gas from the methane generated at the Humacao landfill has the goal of reducing landfill emissions by 90% and replacing fossil fuels and fossil resources. It is the only renewable domestically produced gas in Puerto Rico and provides a more secure energy future for the island.
The use of RNLG will further reduce the company’s greenhouse gas (GHG) emissions in Puerto Rico, on-route to achieve AstraZeneca’s Ambition Zero Carbon. The Company is on track to reduce GHG emissions from its global operations and fleet (Scope 1 and 2) by 98% by 2026 (from a 2015 baseline). AstraZeneca aims to halve its entire value chain footprint (Scope 3) by 2030, on the way to a 90% absolute emissions reduction (from a 2019 baseline) and become science-based net zero by 2045 at the latest.
Continue Reading
#News
#CHP